Novo Drops 3.2% As CEO Eyes Longevity And Aesthetics - Yahoo Finance
Source:Yahoo Entertainment
Novo’s CEO says semaglutide could push the company beyond obesity and diabetes into longevity and appearance-related medicine.
Novo’s CEO says semaglutide could push the company beyond obesity and diabetes into longevity and appearance-related medicine.